| Description | Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is an orally available antiviral agent that inhibits the NS5A region of the hepatitis C virus (HCV) and is used in combination with other oral antiviral agents to treat chronic hepatitis C. Elevations in serum enzyme levels during daclatasvir therapy are uncommon, and it has yet to be convincingly implicated in cases of clinically apparent liver injury with jaundice. |
| Target activity | HCV 1a:50 pM (EC50), HCV 3a:146 pM (EC50), NS5A26-202:210 nM (Kd), HCV 5a:33 pM (EC50), NS5A33-202:8 nM (Kd), HCV 4a:12 pM (EC50), OCI:3.27 µM (IC50), HCV 2a:71 pM (EC50), OATP1B:1.5 µM (IC50), HCV 1b:9 pM (EC50) |
| Synonyms | BMS-790052 dihydrochloride, 盐酸达拉他韦 |
| molecular weight | 811.8 |
| Molecular formula | C40H52Cl2N8O6 |
| CAS | 1009119-65-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 55 mg/mL (67.75 mM) |
| References | 1. Fridell RA et al. Antimicrob Agents ChemOthers. 2010 Sep;54(9):3641-50. |